标题/作者	年份
Alzheimer disease: an update on pathobiology and treatment strategies JM Long, DM Holtzman Cell 179 (2), 312-339	2019
Alzheimer disease DS Knopman, H Amieva, RC Petersen, G Chételat, DM Holtzman, ... Nature reviews Disease primers 7 (1), 33	2021
Synergy between amyloid-β and tau in Alzheimer’s disease MA Busche, BT Hyman Nature neuroscience 23 (10), 1183-1193	2020
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group B Dubois, N Villain, GB Frisoni, GD Rabinovici, M Sabbagh, S Cappa, ... The Lancet Neurology 20 (6), 484-496	2021
The β-secretase BACE1 in Alzheimer’s disease H Hampel, R Vassar, B De Strooper, J Hardy, M Willem, N Singh, J Zhou, ... Biological psychiatry 89 (8), 745-756	2021
The amyloid-β pathway in Alzheimer’s disease H Hampel, J Hardy, K Blennow, C Chen, G Perry, SH Kim, VL Villemagne, ... Molecular psychiatry 26 (10), 5481-5503	2021
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval M Tolar, S Abushakra, JA Hey, A Porsteinsson, M Sabbagh Alzheimer's research & therapy 12, 1-10	2020
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative TK Karikari, AL Benedet, NJ Ashton, J Lantero Rodriguez, A Snellman, ... Molecular psychiatry 26 (2), 429-442	2021
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics E Karran, B De Strooper Nature Reviews Drug Discovery 21 (4), 306-318	2022
Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease N Korte, R Nortley, D Attwell Acta Neuropathologica 140, 793-810	2020
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum A Moscoso, MJ Grothe, NJ Ashton, TK Karikari, JL Rodriguez, A Snellman, ... Brain 144 (1), 325-339	2021
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes CR Jack Jr, HJ Wiste, H Botha, SD Weigand, TM Therneau, DS Knopman, ... Brain 142 (10), 3230-3242	2019
Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging R Ossenkoppele, R Smith, N Mattsson-Carlgren, C Groot, A Leuzy, ... JAMA neurology 78 (8), 961-971	2021
Diagnostic biomarkers of Alzheimer’s disease: a state-of-the-art review R Khoury, E Ghossoub Biomarkers in Neuropsychiatry 1, 100005	2019
Nrf2: a dark horse in Alzheimer's disease treatment A Osama, J Zhang, J Yao, X Yao, J Fang Ageing research reviews 64, 101206	2020
Prevention of dementia in an ageing world: Evidence and biological rationale G Grande, C Qiu, L Fratiglioni Ageing Research Reviews 64, 101045	2020
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease KI Avgerinos, L Ferrucci, D Kapogiannis Ageing research reviews 68, 101339	2021
Neuroinflammation as a factor of neurodegenerative disease: thalidomide analogs as treatments YJ Jung, D Tweedie, MT Scerba, NH Greig Frontiers in Cell and Developmental Biology 7, 313	2019
The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography JS Sanchez, JA Becker, HIL Jacobs, BJ Hanseeuw, S Jiang, AP Schultz, ... Science translational medicine 13 (577), eabc0655	2021
Sleep disturbance forecasts β-amyloid accumulation across subsequent years JR Winer, BA Mander, S Kumar, M Reed, SL Baker, WJ Jagust, ... Current Biology 30 (21), 4291-4298. e3	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。